Oral function in Patients with Spinal Muscular Atrophy

Organizational Data

DRKS-ID:
DRKS00015842
Recruitment Status:
Recruiting complete, study continuing
Date of registration in DRKS:
2019-07-30
Last update in DRKS:
2023-11-28
Registration type:
Prospective

Acronym/abbreviation of the study

No Entry

URL of the study

No Entry

Brief summary in lay language

We measure maximum bite force / endurance and maximum tongue pressure / endurance in patients with spinal muscular atrophy. A fifth outcome parameter is the maximum mouth opening measured by a ruler. The patients receive a therapy with Nusinersen or Risdiplam or no therapy. We hope to evaluate the effect of the therapy on the bulbar function based on the measurements.

Brief summary in scientific language

Spinal muscular atrophy (SMA) is characterized by progressive spinal and bulbar muscle weakness and atrophy caused by the degeneration of alpha-motoneurons. The recent approval of the antisense oligonucleotide nusinersen highlights the need for reliable clinical tools to evaluate motor function in patients with SMA. This study’s aim is to test if oral function measurements are suitable to quantify changes of altered bulbar function during nusinersen therapy. We want to include patients at an advanced state of SMA. In patients in an advanced stage, the maximum bite force and tongue pressure could be a quantitative measure of the bulbar function and thus an alternative to conventional motor scales, which require residual mobility of the extremities and of the head. The aim of this study is to perform isometric strength measurements in SMA patients to show possible changes in oral function indicating changes in bulbar function. Additionally endurance measurements and the measurement od maximum mouth opening are planned. A piezoelectric force sensor registers the maximum bite force in the posterior region recorded by the I-Scan software. Relative bite force changes in different treatment phases are analyzed. Tongue pressure is measured with a hendheld device IOPI. Maximum mouth opening is measured with a ruler.

Health condition or problem studied

ICD10:
G12.1 - Other inherited spinal muscular atrophy
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
We measure oral function (maximum bite force and endurance, maximum tongue pressure and endurance, maximum mouth opening) in patients with spinal muscular atrophy that are treated with Nusinersen (Biogen) or Risdiplam (Roche) at different time points.
Arm 2:
We measure oral function in naive patients with spinal muscular at different time points.

Endpoints

Primary outcome:
Relative changes in oral function. Measured with piezoelectric transducers and an IOPI hendheld device. Measurements are repeated over the course of one year.
Secondary outcome:
Relative change of oral function: maximum mouth opening, measured by a ruler.

Study Design

Purpose:
Other
Retrospective/prospective:
Prospective
Study type:
Non-interventional
Longitudinal/cross-sectional:
Longitudinal study
Study type non-interventional:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study continuing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Poliklinik für Kieferorthopädie, Klinik und Poliklinik für Neurologie Köln
  • University medical center Klinik für Neurologie Essen

Recruitment period and number of participants

Planned study start date:
2019-10-01
Actual study start date:
2020-07-24
Planned study completion date:
2024-12-31
Actual Study Completion Date:
No Entry
Target Sample Size:
50
Final Sample Size:
58

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
50 Years
Additional Inclusion Criteria:
Patients with spinal muscular atrophy type I, II or III.

Exclusion Criteria

Maxmimum mouth opening < 8mm

Addresses

Primary Sponsor

Address:
Poliklinik für Kieferothopädie, Uniklinik Köln
Kerpener Str. 32
50931 Köln
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Poliklinik für Kieferorthopädie, Uniklinik Köln
Dr. Teresa Kruse
Kerpener Str. 32
50931 Köln
Germany
Telephone:
0049 221 478 4712
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Poliklinik für Kieferorthopädie, Uniklinik Köln
Dr. Teresa Kruse
Kerpener Str. 32
50931 Köln
Germany
Telephone:
0049 221 478 4712
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Poliklinik für Kieferorthopädie, Uniklinik Köln
Dr. Teresa Kruse
Kerpener Str. 32
50931 Köln
Germany
Telephone:
0049 221 478 4712
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)

Address:
Biogen GmbH
81677 München
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Poliklinik für Kieferorthopädie, Uniklinik Köln
Kerpener Str. 32
50931 Köln
Germany
Telephone:
0049 221 478 4712
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Medizinischen Fakultät der Universität zu Köln
Gleueler Str. 269
50935 Köln
Germany
Telephone:
+49-221-478 82900
Fax:
+40-221-478 82905
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2019-03-05
Ethics committee number:
19-1137_1
Vote of the Ethics Committee:
Approved
Date of the vote:
2019-06-13

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
Only in the context of scientific publications (e.g. study protocol).

Study protocol and other study documents

Study protocols:
Kruse, Teresa, et al. "The maximum bite force for treatment evaluation in severely affected adult SMA patients—Protocol for a longitudinal study." Frontiers in Neurology 11 (2020): 139.
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry